651
|
Martin LT, Glass M, Dosunmu E, Martin PT. Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors. Hum Pathol 2007; 38:1657-68. [PMID: 17640712 PMCID: PMC2850815 DOI: 10.1016/j.humpath.2007.03.025] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2006] [Revised: 11/28/2006] [Accepted: 03/12/2007] [Indexed: 10/23/2022]
Abstract
Altered glycosylation and/or expression of dystroglycan have been reported in forms of congenital muscular dystrophy as well as in cancers of the breast, colon, and oral epithelium. To date, however, there has been no study of the expression of dystroglycan in pediatric solid tumors. Using a combination of immunostaining on tissue microarrays and immunoblotting of snap-frozen unfixed tissues, we demonstrate a significant reduction in native alpha dystroglycan expression in pediatric alveolar rhabdomyosarcoma (RMS), embryonal RMS, neuroblastoma (NBL), and medulloblastoma, whereas expression of beta dystroglycan, which is cotranslated with alpha dystroglycan, is largely unchanged. Loss of native alpha dystroglycan expression was significantly more pronounced in stage 4 NBL than in pooled samples of stage 1 and stage 2 NBL, suggesting that loss of native alpha dystroglycan expression increases with advancing tumor stage. Neuroblastoma and RMS samples with reduced expression of native alpha dystroglycan also showed reduced laminin binding in laminin overlay experiments. Expression of natively glycosylated alpha dystroglycan was not altered in several other pediatric tumor types when compared with appropriate normal tissue controls. These data provide the first evidence that alpha dystroglycan glycosylation and laminin binding to alpha dystroglycan are altered in certain pediatric solid tumors and suggest that aberrant dystroglycan glycosylation may contribute to tumor cell biology in patients with RMS, medulloblastoma, and NBL.
Collapse
Affiliation(s)
- Laura T Martin
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Ohio State University College of Medicine and Public Health, Columbus, OH 43205, USA.
| | | | | | | |
Collapse
|
652
|
Brunherotti MA, Sobreira C, Rodrigues-Júnior AL, de Assis MR, Terra Filho J, Baddini Martinez JA. Correlations of Egen Klassifikation and Barthel Index scores with pulmonary function parameters in Duchenne muscular dystrophy. Heart Lung 2007; 36:132-9. [PMID: 17362794 DOI: 10.1016/j.hrtlng.2006.07.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2006] [Revised: 07/12/2006] [Accepted: 07/17/2006] [Indexed: 11/27/2022]
Abstract
PURPOSE This study investigated the correlations obtained by using the Egen Klassifikation (EK) and Barthel Index (BI) functional scales and respiratory function parameters in patients with Duchenne muscular dystrophy. METHODS Spirometry, maximal respiratory pressures, and arterial blood gases were analyzed and graded according to the EK and BI scales in 26 patients. They were classified as high or low risk for introduction of noninvasive ventilation according to the respiratory function. RESULTS The EK and BI scales significantly correlated with forced vital capacity, forced expiratory volume in 1 second, and maximal respiratory pressures. The worse the functional performance, the worse the respiratory measurements. The degree of correlation between the functional scales and each respiratory parameter was similar. An EK of 21 or higher predicted high risk for the introduction of noninvasive ventilation. CONCLUSIONS EK and BI scales similarly correlated with the degree of respiratory involvement in Duchenne muscular dystrophy. The EK scale was superior in detecting subjects with a higher risk for introduction of noninvasive ventilation.
Collapse
Affiliation(s)
- Marisa Afonso Brunherotti
- Pulmonary Division, Internal Medicine Department, Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil
| | | | | | | | | | | |
Collapse
|
653
|
Hinkle RT, Lefever FR, Dolan ET, Reichart DL, Dietrich JA, Gropp KE, Thacker RI, Demuth JP, Stevens PJ, Qu XA, Varbanov AR, Wang F, Isfort RJ. Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice. BMC Med 2007; 5:18. [PMID: 17626629 PMCID: PMC1936998 DOI: 10.1186/1741-7015-5-18] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2006] [Accepted: 07/12/2007] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND Duchenne muscular dystrophy results from mutation of the dystrophin gene, causing skeletal and cardiac muscle loss of function. The mdx mouse model of Duchenne muscular dystrophy is widely utilized to evaluate the potential of therapeutic regimens to modulate the loss of skeletal muscle function associated with dystrophin mutation. Importantly, progressive loss of diaphragm function is the most consistent striated muscle effect observed in the mdx mouse model, which is the same as in patients suffering from Duchenne muscular dystrophy. METHODS Using the mdx mouse model, we have evaluated the effect that corticotrophin releasing factor 2 receptor (CRF2R) agonist treatment has on diaphragm function, morphology and gene expression. RESULTS We have observed that treatment with the potent CRF2R-selective agonist PG-873637 prevents the progressive loss of diaphragm specific force observed during aging of mdx mice. In addition, the combination of PG-873637 with glucocorticoids not only prevents the loss of diaphragm specific force over time, but also results in recovery of specific force. Pathological analysis of CRF2R agonist-treated diaphragm muscle demonstrates that treatment reduces fibrosis, immune cell infiltration, and muscle architectural disruption. Gene expression analysis of CRF2R-treated diaphragm muscle showed multiple gene expression changes including globally decreased immune cell-related gene expression, decreased extracellular matrix gene expression, increased metabolism-related gene expression, and, surprisingly, modulation of circadian rhythm gene expression. CONCLUSION Together, these data demonstrate that CRF2R activation can prevent the progressive degeneration of diaphragm muscle associated with dystrophin gene mutation.
Collapse
Affiliation(s)
- Richard T Hinkle
- Research Division, Procter & Gamble Pharmaceuticals, Mason, OH, USA
| | - Frank R Lefever
- Research Division, Procter & Gamble Pharmaceuticals, Mason, OH, USA
| | | | | | | | - Kathryn E Gropp
- Research Division, Procter & Gamble Pharmaceuticals, Mason, OH, USA
| | - Robert I Thacker
- Department of Pathobiology and Molecular Medicine, University of Cincinnati, Cincinnati, OH, USA
| | - Jeffrey P Demuth
- Research Division, Procter & Gamble Pharmaceuticals, Mason, OH, USA
| | - Paula J Stevens
- Research Division, Procter & Gamble Pharmaceuticals, Mason, OH, USA
| | - Xiaoyan A Qu
- Research Division, Procter & Gamble Pharmaceuticals, Mason, OH, USA
| | - Alex R Varbanov
- Research Division, Procter & Gamble Pharmaceuticals, Mason, OH, USA
| | - Feng Wang
- Research Division, Procter & Gamble Pharmaceuticals, Mason, OH, USA
| | - Robert J Isfort
- Research Division, Procter & Gamble Pharmaceuticals, Mason, OH, USA
| |
Collapse
|
654
|
McCarthy JJ, Esser KA, Andrade FH. MicroRNA-206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse. Am J Physiol Cell Physiol 2007; 293:C451-7. [PMID: 17459947 DOI: 10.1152/ajpcell.00077.2007] [Citation(s) in RCA: 105] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
MicroRNAs are highly conserved, noncoding RNAs involved in posttranscriptional gene silencing. MicroRNAs have been shown to be involved in a range of biological processes, including myogenesis and muscle regeneration. The objective of this study was to test the hypothesis that microRNA expression is altered in dystrophic muscle, with the greatest change occurring, of the muscles examined, in the diaphragm. The expression of the muscle-enriched microRNAs was determined in the soleus, plantaris, and diaphragm muscles of control and dystrophin-deficient ( mdx) mice by semiquantitative PCR. In the soleus and plantaris, expression of the mature microRNA 133a (miR-133a) and miR-206, respectively, was decreased by ∼25%, whereas in the diaphragm, miR-206 expression increased by 4.5-fold relative to control. The increased expression of miR-206 in the mdx diaphragm was paralleled by a 4.4-fold increase in primary miRNA-206 (pri-miRNA-206) transcript level. Expression of Myod1 was elevated 2.7-fold only in the mdx diaphragm, consistent with an earlier finding demonstrating Myod1 can activate pri-miRNA-206 transcription. Transcript levels of Drosha and Dicer, major components of microRNA biogenesis pathway, were unchanged in mdx muscle, suggesting the pathway is not altered under dystrophic conditions. Previous in vitro analysis found miR-206 was capable of repressing utrophin expression; however, under dystrophic conditions, both utrophin transcript and protein levels were significantly increased by 69% and 3.9-fold, respectively, a finding inconsistent with microRNA regulation. These results are the first to report alterations in expression of muscle-enriched microRNAs in skeletal muscle of the mdx mouse, suggesting microRNAs may have a role in the pathophysiology of muscular dystrophy.
Collapse
Affiliation(s)
- John J McCarthy
- Dept. of Physiology, University of Kentucky Medical Center, 800 Rose St., Lexington, KY 40536-0298, USA.
| | | | | |
Collapse
|
655
|
Zanotti S, Saredi S, Ruggieri A, Fabbri M, Blasevich F, Romaggi S, Morandi L, Mora M. Altered extracellular matrix transcript expression and protein modulation in primary Duchenne muscular dystrophy myotubes. Matrix Biol 2007; 26:615-24. [PMID: 17662584 DOI: 10.1016/j.matbio.2007.06.004] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2007] [Revised: 06/11/2007] [Accepted: 06/20/2007] [Indexed: 11/19/2022]
Abstract
Extent of muscle fibrosis contributes to disease severity in muscular dystrophies. To investigate whether extracellular matrix (ECM) components contribute to the severe fibrosis observed in Duchenne muscular dystrophy (DMD) skeletal muscle, we quantitated several ECM components (transcripts and proteins) in primary DMD and control myotube cultures. We evaluated the fibrogenic transforming growth factor- beta1 (TGF-beta1); the small pleiotropic proteoglycan decorin, involved in collagen fibrillogenesis and TGF-beta1 modulation; metalloproteinases MMP-2 and MMP-9; tissue inhibitors of metalloproteinase (TIMP) 1, 2 and 3; collagens I and VI; and the tissue factor myostatin that inhibits muscle growth. Dystrophic myotube cultures had significantly lower levels of decorin mRNA, as also observed in DMD muscle biopsies, and significantly higher levels of TGF-beta1, myostatin, and collagens I and VI. MMP-2, TIMP-1 and TIMP-2 transcript levels were also significantly increased in DMD, but MMP-9 and TIMP-3 transcripts were unchanged. By zymography, MMP-2 activity was significantly higher in DMD than control. Protein levels were similar in DMD and controls but myostatin protein was significantly increased in DMD. We have found that transcript expression and protein modulation of several ECM components is altered in DMD muscle cells in vitro, indicating that these cells contribute fundamentally to the pathological process, since the inflammation and degeneration characterizing DMD muscle in vivo are presumably absent in culture. Our findings that myostatin-potent inhibitor of satellite cell activation and muscle renewal--is increased, and that decorin-binder and downregulator of TGFbeta1 and myostatin--is decreased, may have implications for DMD therapy to reduce muscle fibrosis.
Collapse
Affiliation(s)
- S Zanotti
- Neuromuscular Diseases and Neuroimmunology Unit, Foundation IRCCS Neurological Institute C. Besta, Milano, Italy
| | | | | | | | | | | | | | | |
Collapse
|
656
|
McClure WC, Rabon RE, Ogawa H, Tseng BS. Upregulation of the creatine synthetic pathway in skeletal muscles of mature mdx mice. Neuromuscul Disord 2007; 17:639-50. [PMID: 17588756 PMCID: PMC2706264 DOI: 10.1016/j.nmd.2007.04.008] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2006] [Revised: 03/23/2007] [Accepted: 04/02/2007] [Indexed: 11/24/2022]
Abstract
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular human disease caused by dystrophin deficiency. The mdx mouse lacks dystrophin protein, yet does not exhibit the debilitating DMD phenotype. Investigating compensatory mechanisms in the mdx mouse may shed new insights into modifying DMD pathogenesis. This study targets two metabolic genes, guanidinoacetate methyltransferase (GAMT) and arginine:glycine amidinotransferase (AGAT) which are required for creatine synthesis. We show that GAMT and AGAT mRNA are up-regulated 5.4- and 1.9-fold respectively in adult mdx muscle compared to C57. In addition, GAMT protein expression is up-regulated at least 2.5-fold in five different muscles of mdx vs. control. Furthermore, we find GAMT immunoreactivity in up to 80% of mature mdx muscle fibers in addition to small regenerating fibers and rare revertants; while GAMT immunoreactivity is equal to background levels in all muscle fibers of mature C57 mice. The up-regulation of the creatine synthetic pathway may help maintain muscle creatine levels and limit cellular energy failure in leaky mdx skeletal muscles. These results may help better understand the mild phenotype of the mdx mouse and may offer new treatment horizons for DMD.
Collapse
Affiliation(s)
- Warren C McClure
- Department of Pediatrics, University of Colorado-Denver Health Science Center, The Children's Hospital Fitzsimons Campus, Aurora, CO 80045, USA
| | | | | | | |
Collapse
|
657
|
Xiong F, Xiao S, Peng F, Zheng H, Yu M, Ruan Y, Li W, Shang Y, Zhao C, Zhou W, Chen H, Chamberlain JS, Fang L, Zhang C. Herpes Simplex Virus VP22 Enhances Adenovirus-Mediated Microdystrophin Gene Transfer to Skeletal Muscles in Dystrophin-Deficient (mdx) Mice. Hum Gene Ther 2007; 18:490-501. [PMID: 17550336 DOI: 10.1089/hum.2006.155] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
One of the obstacles to efficient vector-mediated gene therapy for Duchenne's muscular dystrophy (DMD) is its limited transduction efficiency. The VP22 tegument protein of herpes simplex virus type 1 (HSV-1) is able to cross biological membranes and translocate the VP22 fusion protein from transfected primary cells to surrounding cells and improve the outcome of gene transfer. To improve the efficiency of vector-mediated gene therapy and to investigate the utility of the intercellular trafficking properties of VP22-linked protein for the treatment for DMD, the recombinant adenoviruses Ad-VP22, Ad-MICDYS, and Ad-VP22-MICDYS were constructed and the VP22-mediated shuttle effect was evaluated both in vitro and in vivo. About 92 +/- 3.6% of cells were microdystrophin positive 48 hr postinfection with Ad-VP22-MICDYS. The number of centralized nuclei in Ad-VP22-MICDYS-transduced tibialis anterior (TA) muscle was significantly reduced, from 78 +/- 5.2 to 20 +/- 2.5%, by 2 weeks postinjection. By 2 months postinjection, the average number of microdystrophin-positive fibers in TA muscle injected with Ad-VP22-MICDYS was 2.2 times more than that of TA muscle injected with Ad-MICDYS. Ad-VP22-MICDYS led to significant recovery of force-producing capabilities in TA muscle. These results demonstrate that VP22 greatly augmented adenovirus-mediated microdystrophin delivery to C2C12 cells and to the skeletal muscles of dystrophin-deficient (mdx) mice. These results highlight the efficiency of VP22-mediated intercellular protein delivery for the potential therapy of DMD and suggest that VP22 may be a promising tool with which to enhance the efficacy of adenoviral gene transfer for somatic gene therapy of DMD.
Collapse
MESH Headings
- Adenoviridae/genetics
- Adenoviridae Infections/genetics
- Adenoviridae Infections/metabolism
- Adenoviridae Infections/therapy
- Animals
- Dystrophin/genetics
- Dystrophin/therapeutic use
- Female
- Gene Expression
- Gene Transfer Techniques
- Genetic Therapy/methods
- Genetic Vectors/genetics
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Inbred mdx
- Muscle Contraction/physiology
- Muscle Fibers, Skeletal/chemistry
- Muscle, Skeletal/chemistry
- Muscle, Skeletal/cytology
- Muscle, Skeletal/metabolism
- Muscular Dystrophy, Animal/genetics
- Muscular Dystrophy, Animal/metabolism
- Muscular Dystrophy, Animal/therapy
- Phenotype
- Phosphoproteins/genetics
- Phosphoproteins/metabolism
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/metabolism
- Transduction, Genetic
- Transfection
- Viral Structural Proteins/genetics
- Viral Structural Proteins/metabolism
Collapse
Affiliation(s)
- Fu Xiong
- Department of Neurology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, People's Republic of China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
658
|
Dye WW, Gleason RL, Wilson E, Humphrey JD. Altered biomechanical properties of carotid arteries in two mouse models of muscular dystrophy. J Appl Physiol (1985) 2007; 103:664-72. [PMID: 17525297 DOI: 10.1152/japplphysiol.00118.2007] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Muscular dystrophy is characterized by skeletal muscle weakness and wasting, but little is known about possible alterations to the vasculature. Many muscular dystrophies are caused by a defective dystrophin-glycoprotein complex (DGC), which plays an important role in mechanotransduction and maintenance of structural integrity in muscle cells. The DGC is a group of membrane-associated proteins, including dystrophin and sarcoglycan-delta, that helps connect the cytoskeleton of muscle cells to the extracellular matrix. In this paper, mice lacking genes encoding dystrophin (mdx) or sarcoglycan-delta (sgcd-/-) were studied to detect possible alterations to vascular wall mechanics. Pressure-diameter and axial force-length tests were performed on common carotid arteries from mdx, sgcd-/-, and wild-type mice in active (basal) and passive smooth muscle states, and functional responses to three vasoactive compounds were determined at constant pressure and length. Apparent biomechanical differences included the following: mdx and sgcd-/- arteries had decreased distensibilities in pressure-diameter tests, with mdx arteries exhibiting elevated circumferential stresses, and mdx and sgcd-/- arteries generated elevated axial loads and stresses in axial force-length tests. Interestingly, however, mdx and sgcd-/- arteries also had significantly lower in vivo axial stretches than did the wild type. Accounting for this possible adaptation largely eliminated the apparent differences in circumferential and axial stiffness, thus suggesting that loss of DGC proteins may induce adaptive biomechanical changes that can maintain overall wall mechanics in response to normal loads. Nevertheless, there remains a need to understand better possible vascular adaptations in response to sustained altered loads in patients with muscular dystrophy.
Collapse
Affiliation(s)
- W W Dye
- Dept. of Biomedical Engineering, M. E. DeBakey Institute, Texas A&M University, College Station, TX 77843-3120, USA
| | | | | | | |
Collapse
|
659
|
Buvoli M, Buvoli A, Leinwand LA. Interplay between exonic splicing enhancers, mRNA processing, and mRNA surveillance in the dystrophic Mdx mouse. PLoS One 2007; 2:e427. [PMID: 17487273 PMCID: PMC1855434 DOI: 10.1371/journal.pone.0000427] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2007] [Accepted: 04/15/2007] [Indexed: 02/05/2023] Open
Abstract
Background Pre-mRNA splicing, the removal of introns from RNA, takes place within the spliceosome, a macromolecular complex composed of five small nuclear RNAs and a large number of associated proteins. Spliceosome assembly is modulated by the 5′ and 3′ splice site consensus sequences situated at the ends of each intron, as well as by exonic and intronic splicing enhancers/silencers recognized by SR and hnRNP proteins. Nonsense mutations introducing a premature termination codon (PTC) often result in the activation of cellular quality control systems that reduce mRNA levels or alter the mRNA splicing pattern. The mdx mouse, a commonly used genetic model for Duchenne muscular dystrophy (DMD), lacks dystrophin by virtue of a premature termination codon (PTC) in exon 23 that also severely reduces the level of dystrophin mRNA. However, the effect of the mutation on dystrophin RNA processing has not yet been described. Methodology/Principal Finding Using combinations of different biochemical and cellular assays, we found that the mdx mutation partially disrupts a multisite exonic splicing enhancer (ESE) that is recognized by a 40 kDa SR protein. In spite of the presence of an inefficient intron 22 3′ splice site containing the rare GAG triplet, the mdx mutation does not activate nonsense-associated altered splicing (NAS), but induces exclusively nonsense-mediated mRNA decay (NMD). Functional binding sites for SR proteins were also identified in exon 22 and 24, and in vitro experiments show that SR proteins can mediate direct association between exon 22, 23, and 24. Conclusions/Significance Our findings highlight the complex crosstalk between trans-acting factors, cis-elements and the RNA surveillance machinery occurring during dystrophin mRNA processing. Moreover, they suggest that dystrophin exon–exon interactions could play an important role in preventing mdx exon 23 skipping, as well as in facilitating the pairing of committed splice sites.
Collapse
Affiliation(s)
- Massimo Buvoli
- Department of Molecular, Cellular and Developmental Biology, University of Colorado at Boulder, Boulder, Colorado, United States of America
| | - Ada Buvoli
- Department of Molecular, Cellular and Developmental Biology, University of Colorado at Boulder, Boulder, Colorado, United States of America
| | - Leslie A. Leinwand
- Department of Molecular, Cellular and Developmental Biology, University of Colorado at Boulder, Boulder, Colorado, United States of America
- * To whom correspondence should be addressed. E-mail:
| |
Collapse
|
660
|
Hanft LM, Bogan DJ, Mayer U, Kaufman SJ, Kornegay JN, Ervasti JM. Cytoplasmic gamma-actin expression in diverse animal models of muscular dystrophy. Neuromuscul Disord 2007; 17:569-74. [PMID: 17475492 PMCID: PMC1993539 DOI: 10.1016/j.nmd.2007.03.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2006] [Revised: 02/26/2007] [Accepted: 03/05/2007] [Indexed: 11/23/2022]
Abstract
We recently showed that cytoplasmic gamma-actin (gamma(cyto)-actin) is dramatically elevated in striated muscle of dystrophin-deficient mdx mice. Here, we demonstrate that gamma(cyto)-actin is markedly increased in golden retriever muscular dystrophy (GRMD), which better recapitulates the dystrophinopathy phenotype in humans. Gamma(cyto)-Actin was also elevated in muscle from alpha-sarcoglycan null mice, but not in several other dystrophic animal models, including mice deficient in beta-sarcoglycan, alpha-dystrobrevin, laminin-2, or alpha7 integrin. Muscle from mice lacking dystrophin and utrophin also expressed elevated gamma(cyto)-actin, which was not restored to normal by transgenic overexpression of alpha7 integrin. However, gamma(cyto)-actin was further elevated in skeletal muscle from GRMD animals treated with the glucocorticoid prednisone at doses shown to improve the dystrophic phenotype and muscle function. These data suggest that elevated gamma(cyto)-actin is part of a compensatory cytoskeletal remodeling program that may partially stabilize dystrophic muscle in some cases where the dystrophin-glycoprotein complex is compromised.
Collapse
Affiliation(s)
- Laurin M. Hanft
- Department of Physiology, University of Wisconsin, Madison, WI
| | - Daniel J. Bogan
- College of Veterinary Medicine and Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO
| | - Ulrike Mayer
- Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, Manchester, UK
| | - Stephen J. Kaufman
- Department of Cell and Developmental Biology, University of Illinois, Urbana, IL
| | - Joe N. Kornegay
- College of Veterinary Medicine and Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO
| | | |
Collapse
|
661
|
van der Plas MC, Pilgram GSK, de Jong AWM, Bansraj MRKS, Fradkin LG, Noordermeer JN. Drosophila Dystrophin is required for integrity of the musculature. Mech Dev 2007; 124:617-30. [PMID: 17543506 DOI: 10.1016/j.mod.2007.04.003] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2006] [Revised: 03/17/2007] [Accepted: 04/16/2007] [Indexed: 11/21/2022]
Abstract
Duchenne muscular dystrophy is caused by mutations in the dystrophin gene and is characterized by progressive muscle wasting. The highly conserved dystrophin gene encodes a number of protein isoforms. The Dystrophin protein is part of a large protein assembly, the Dystrophin glycoprotein complex, which stabilizes the muscle membrane during contraction and acts as a scaffold for signaling molecules. How the absence of Dystrophin results in the onset of muscular dystrophy remains unclear. Here, we have used transgenic RNA interference to examine the roles of the Drosophila Dystrophin isoforms in muscle. We previously reported that one of the Drosophila Dystrophin orthologs, the DLP2 isoform, is not required to maintain muscle integrity, but plays a role in neuromuscular homeostasis by regulating neurotransmitter release. In this report, we show that reduction of all Dystrophin isoform expression levels in the musculature does not apparently affect myogenesis or muscle attachment, but results in progressive muscle degeneration in larvae and adult flies. We find that a recently identified Dystrophin isoform, Dp117, is expressed in the musculature and is required for muscle integrity. Muscle fibers with reduced levels of Dp117 display disorganized actin-myosin filaments and the cellular hallmarks of necrosis. Our results indicate the existence of at least two possibly separate roles of dystrophin in muscle, maintaining synaptic homeostasis and preserving the structural stability of the muscle.
Collapse
Affiliation(s)
- Mariska C van der Plas
- Laboratory of Developmental Neurobiology, Department of Molecular and Cell Biology, Leiden University Medical Center, Einthovenweg 20, PO Box 9600, 2300 RC Leiden, The Netherlands
| | | | | | | | | | | |
Collapse
|
662
|
Anastasi G, Cutroneo G, Sidoti A, Rinaldi C, Bruschetta D, Rizzo G, D'Angelo R, Tarone G, Amato A, Favaloro A. Sarcoglycan subcomplex expression in normal human smooth muscle. J Histochem Cytochem 2007; 55:831-43. [PMID: 17438352 DOI: 10.1369/jhc.6a7145.2007] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The sarcoglycan complex (SGC) is a multimember transmembrane complex interacting with other members of the dystrophin-glycoprotein complex (DGC) to provide a mechanosignaling connection from the cytoskeleton to the extracellular matrix. The SGC consists of four proteins (alpha, beta, gamma, and delta). A fifth sarcoglycan subunit, epsilon-sarcoglycan, shows a wider tissue distribution. Recently, a novel sarcoglycan, the zeta-sarcoglycan, has been identified. All reports about the structure of SGC showed a common assumption of a tetrameric arrangement of sarcoglycans. Addressing this issue, our immunofluorescence and molecular results showed, for the first time, that all sarcoglycans are always detectable in all observed samples. Therefore, one intriguing possibility is the existence of a pentameric or hexameric complex considering zeta-sarcoglycan of SGC, which could present a higher or lower expression of a single sarcoglycan in conformity with muscle type--skeletal, cardiac, or smooth--or also in conformity with the origin of smooth muscle.
Collapse
Affiliation(s)
- Giuseppe Anastasi
- Department of Biomorphology and Biotechnologies, University of Messina, Via Consolare Valeria, 1 IT-98125, Messina, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
663
|
Pinto ML, Tokunaga HHVO, Souccar C, Schoorlemmer GHM, Lapa RDCRDS. Morphological changes in the trigemino-rubral pathway in dystrophic (mdx) mice. Neurosci Lett 2007; 416:175-9. [PMID: 17324512 DOI: 10.1016/j.neulet.2007.02.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2006] [Revised: 01/31/2007] [Accepted: 02/01/2007] [Indexed: 11/16/2022]
Abstract
The lack of dystrophin that causes Duchenne muscle disease affects not only the muscles but also the central nervous system. Dystrophin-deficient mdx mice present changes in several brain fiber systems. We compared the projections from the trigeminal sensory nuclear complex to the red nucleus in control and mdx mice using retrograde tracers. Injection of 200 nL 2% fluorogold into the red nucleus caused labeling in the mesencephalic trigeminal nucleus, the principal sensory nucleus and the oral, interpolar, and caudal subnuclei of the spinal trigeminal nucleus in both control and mdx mice. Injection of latex microbeads labeled with rhodamine and fluorescein gave results similar to those seen with fluorogold. The number of labeled neurons in the trigeminal sensory nuclear complex was significantly reduced in mdx mice. In the oral subnucleus of the spinal trigeminal nucleus this reduction was 50%. These results indicate that the trigemino-rubral pathway is reduced in dystrophin-deficient mice.
Collapse
Affiliation(s)
- Magali Luci Pinto
- Department of Histology, Universidade Federal de São Paulo, São Paulo, Brazil
| | | | | | | | | |
Collapse
|
664
|
Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, Li ZW, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner KL, Rafael-Fortney JA, Karin M, Tidball JG, Baldwin AS, Guttridge DC. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007; 117:889-901. [PMID: 17380205 PMCID: PMC1821069 DOI: 10.1172/jci30556] [Citation(s) in RCA: 346] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2006] [Accepted: 02/06/2007] [Indexed: 01/25/2023] Open
Abstract
Duchenne muscular dystrophy (DMD) is a lethal X-linked disorder associated with dystrophin deficiency that results in chronic inflammation and severe skeletal muscle degeneration. In DMD mouse models and patients, we find that IkappaB kinase/NF-kappaB (IKK/NF-kappaB) signaling is persistently elevated in immune cells and regenerative muscle fibers. Ablation of 1 allele of the p65 subunit of NF-kappaB was sufficient to improve pathology in mdx mice, a model of DMD. In addition, conditional deletion of IKKbeta in mdx mice elucidated that NF-kappaB functions in activated macrophages to promote inflammation and muscle necrosis and in skeletal muscle fibers to limit regeneration through the inhibition of muscle progenitor cells. Furthermore, specific pharmacological inhibition of IKK resulted in improved pathology and muscle function in mdx mice. Collectively, these results underscore the critical role of NF-kappaB in the progression of muscular dystrophy and suggest the IKK/NF-kappaB signaling pathway as a potential therapeutic target for DMD.
Collapse
Affiliation(s)
- Swarnali Acharyya
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - S. Armando Villalta
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Nadine Bakkar
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Tepmanas Bupha-Intr
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Paul M.L. Janssen
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Micheal Carathers
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Zhi-Wei Li
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Amer A. Beg
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Sankar Ghosh
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Zarife Sahenk
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Michael Weinstein
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Katherine L. Gardner
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Jill A. Rafael-Fortney
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Michael Karin
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - James G. Tidball
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Albert S. Baldwin
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| | - Denis C. Guttridge
- Human Cancer Genetics Program and Department of
Molecular Virology, Immunology and Medical Genetics, The Ohio State University
College of Medicine, Columbus, Ohio, USA. Department of
Physiological Science, UCLA, Los Angeles, California, USA.
Department of Physiology and Cell Biology, The Ohio State University
College of Medicine, Columbus, Ohio, USA. H. Lee Moffitt Cancer
Center and Research Institute, University of South Florida, Tampa, Florida, USA.
Department of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut, USA. Columbus
Children’s Research Institute, Columbus, Ohio, USA.
Department of Molecular Genetics and Department of
Molecular and Cellular Biochemistry, The Ohio State University College of Medicine,
Columbus, Ohio, USA. Department of Pharmacology, UCSD, San Diego,
California, USA. University of North Carolina at Chapel Hill and
TheraLogics Inc., Research Triangle Park, North Carolina, USA. The
Ohio State University Comprehensive Cancer Center — Arthur G. James
Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
| |
Collapse
|
665
|
Lynch GS, Schertzer JD, Ryall JG. Therapeutic approaches for muscle wasting disorders. Pharmacol Ther 2007; 113:461-87. [PMID: 17258813 DOI: 10.1016/j.pharmthera.2006.11.004] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2006] [Revised: 11/10/2006] [Accepted: 11/10/2006] [Indexed: 12/12/2022]
Abstract
Muscle wasting and weakness are common in many disease states and conditions including aging, cancer cachexia, sepsis, denervation, disuse, inactivity, burns, HIV-acquired immunodeficiency syndrome (AIDS), chronic kidney or heart failure, unloading/microgravity, and muscular dystrophies. Although the maintenance of muscle mass is generally regarded as a simple balance between protein synthesis and protein degradation, these mechanisms are not strictly independent, but in fact they are coordinated by a number of different and sometimes complementary signaling pathways. Clearer details are now emerging about these different molecular pathways and the extent to which these pathways contribute to the etiology of various muscle wasting disorders. Therapeutic strategies for attenuating muscle wasting and improving muscle function vary in efficacy. Exercise and nutritional interventions have merit for slowing the rate of muscle atrophy in some muscle wasting conditions, but in most cases they cannot halt or reverse the wasting process. Hormonal and/or other drug strategies that can target key steps in the molecular pathways that regulate protein synthesis and protein degradation are needed. This review describes the signaling pathways that maintain muscle mass and provides an overview of some of the major conditions where muscle wasting and weakness are indicated. The review provides details on some therapeutic strategies that could potentially attenuate muscle atrophy, promote muscle growth, and ultimately improve muscle function. The emphasis is on therapies that can increase muscle mass and improve functional outcomes that will ultimately lead to improvement in the quality of life for affected patients.
Collapse
Affiliation(s)
- Gordon S Lynch
- Basic and Clinical Myology Laboratory, Department of Physiology, The University of Melbourne, Victoria 3010, Australia.
| | | | | |
Collapse
|
666
|
Xu R, Camboni M, Martin PT. Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: evidence for a utrophin-independent mechanism. Neuromuscul Disord 2007; 17:209-20. [PMID: 17300937 PMCID: PMC1905823 DOI: 10.1016/j.nmd.2006.12.004] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2006] [Revised: 11/15/2006] [Accepted: 12/04/2006] [Indexed: 11/22/2022]
Abstract
Overexpression of the cytotoxic T cell (CT) GalNAc transferase (Galgt2) in the skeletal muscles of transgenic mdx mice has been reported to inhibit the development of muscular dystrophy. The profound effect of Galgt2 on muscular dystrophy in transgenic mice, where overexpression is begins from embryonic stages, is complicated by its additional effects on muscle growth and neuromuscular structure. Here, we use adeno-associated virus (AAV) to show that overexpression of Galgt2 in skeletal myofibers in the early postnatal period is equally effective in inhibiting muscular dystrophy, but that it does so without altering muscle growth or neuromuscular structure. Unlike embryonic overexpression, postnatal overexpression of Galgt2 did not reproducibly increase the expression of utrophin, synaptic laminins, or dystrophin-associated glycoproteins along infected myofibers. Moreover, Galgt2 overexpression inhibited muscular dystrophy to the same extent in utrophin-deficient mdx muscles as it did in utrophin-expressing mdx muscles. Thus, Galgt2 is a molecular target for therapy in DMD that can be utilized in a manner that separates its clinical benefit from its effects on development, and its clinical benefit is distinct from that achieved by utrophin.
Collapse
Affiliation(s)
- Rui Xu
- Center for Gene Therapy, Columbus Children's Research Institute, Department of Pediatrics, Ohio State University College of Medicine and Public Health, 700 Children's Drive, Columbus, OH 43205, USA
| | | | | |
Collapse
|
667
|
Danièle N, Richard I, Bartoli M. Ins and outs of therapy in limb girdle muscular dystrophies. Int J Biochem Cell Biol 2007; 39:1608-24. [PMID: 17339125 DOI: 10.1016/j.biocel.2007.02.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2006] [Revised: 02/02/2007] [Accepted: 02/05/2007] [Indexed: 12/11/2022]
Abstract
Muscular dystrophies are hereditary degenerative muscle diseases that cause life-long disability in patients. They comprise the well-known Duchenne Muscular Dystrophy (DMD) but also the group of Limb Girdle Muscular Dystrophies (LGMD) which account for a third to a fourth of DMD cases. From the clinical point of view, LGMD are characterised by predominant effects on the proximal limb muscles. The LGMD group is still growing today and consists of 19 autosomal dominant and recessive forms (LGMD1A to LGMD1G and LGMD2A to LGMD2M). The proteins involved are very diverse and include sarcomeric, sarcolemmal and enzymatic proteins. With respect to this variability and in line with the intense search for a potent therapeutic approach for DMD, many different strategies have been tested in rodent models. These include replacing the lost function by gene transfer or stem cell transplantation, using a related protein for functional substitution, increasing muscle mass, or blocking the molecular pathological mechanisms by pharmacological means to alleviate the symptoms. The purpose of this review is to summarize current data arising from these preclinical studies and to examine the potential of the tested strategies to lead to clinical applications.
Collapse
|
668
|
Haines N, Stewart BA. Functional roles for beta1,4-N-acetlygalactosaminyltransferase-A in Drosophila larval neurons and muscles. Genetics 2007; 175:671-9. [PMID: 17151241 PMCID: PMC1800592 DOI: 10.1534/genetics.106.065565] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2006] [Accepted: 11/07/2006] [Indexed: 11/18/2022] Open
Abstract
Adult Drosophila mutant for the glycosyltransferase beta1,4-N-acetlygalactosaminyltransferase-A (beta4GalNAcTA) display an abnormal locomotion phenotype, indicating a role for this enzyme, and the glycan structures that it generates, in the neuromuscular system. To investigate the functional role of this enzyme in more detail, we turned to the accessible larval neuromuscular system and report here that larvae mutant for beta4GalNAcTA display distinct nerve and muscle phenotypes. Mutant larvae exhibit abnormal backward crawling, reductions in nerve terminal bouton number, decreased spontaneous transmitter-release frequency, and short, wide muscles. This muscle shape change appears to result from hypercontraction since the individual sarcomeres are shorter in mutant muscles. Analysis of muscle calcium signals showed altered calcium handling in the mutant, suggesting a mechanism by which hypercontraction could occur. All of these phenotypes can be rescued by a transgene carrying the beta4GalNAcTA genomic region. Tissue-specific expression, using the Gal4-UAS system, reveals that neural expression rescues the mutant crawling phenotype, while muscle expression rescues the muscle defect. Tissue-specific expression did not appear to rescue the decrease in neuromuscular junction bouton number, suggesting that this defect arises from cooperation between nerve and muscle. Altogether, these results suggest that beta4GalNAcTA has at least three distinct functional roles.
Collapse
Affiliation(s)
- Nicola Haines
- Department of Biology, University of Toronto, Mississauga, Ontario L5L 1C6, Canada.
| | | |
Collapse
|
669
|
Odom GL, Gregorevic P, Chamberlain JS. Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. BIOCHIMICA ET BIOPHYSICA ACTA 2007; 1772:243-62. [PMID: 17064882 PMCID: PMC1894910 DOI: 10.1016/j.bbadis.2006.09.007] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2006] [Revised: 09/16/2006] [Accepted: 09/20/2006] [Indexed: 02/07/2023]
Abstract
Much progress has been made over the past decade elucidating the molecular basis for a variety of muscular dystrophies (MDs). Accordingly, there are examples of mouse models of MD whose disease progression has been halted in large part with the use of viral vector technology. Even so, we must acknowledge significant limitations of present vector systems that must be overcome prior to successful treatment of humans with such approaches. This review will present a variety of viral-mediated therapeutic strategies aimed at counteracting the muscle-wasting symptoms associated with muscular dystrophy. We include viral vector systems used for muscle gene transfer, with a particular emphasis on adeno-associated virus. Findings of several encouraging studies focusing on repair of the mutant dystrophin gene are also included. Lastly, we present a discussion of muscle compensatory therapeutics being considered that include pathways involved in the up-regulation of utrophin, promotion of cellular adhesion, enhancement of muscle mass, and antagonism of the inflammatory response. Considering the complexity of the muscular dystrophies, it appears likely that a multilayered approach tailored to a patient sub-group may be warranted in order to effectively contest the progression of this devastating disease.
Collapse
Affiliation(s)
- Guy L. Odom
- Department of Neurology Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA, 98195-7720, USA
| | - Paul Gregorevic
- Department of Neurology Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA, 98195-7720, USA
| | - Jeffrey S. Chamberlain
- Department of Neurology Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA, 98195-7720, USA
| |
Collapse
|
670
|
Suchyna TM, Sachs F. Mechanosensitive channel properties and membrane mechanics in mouse dystrophic myotubes. J Physiol 2007; 581:369-87. [PMID: 17255168 PMCID: PMC2075208 DOI: 10.1113/jphysiol.2006.125021] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Muscular dystrophy is associated with increased activity of mechanosensitive channels (MSCs) and increased cell calcium levels. MSCs in patches from mdx mouse myotubes have higher levels of resting activity, compared to patches from wild-type mice, and a pronounced latency of activation and deactivation. Measurements of patch capacitance and geometry reveal that the differences are linked to cortical membrane mechanics rather than to differences in channel gating. We found unexpectedly that patches from mdx mice are strongly curved towards the pipette tip by actin pulling normal to the membrane. This force produces a substantial tension (approximately 5 mN m(-1)) that can activate MSCs in the absence of overt stimulation. The inward curvature of patches from mdx mice is eliminated by actin inhibitors. Applying moderate suction to the pipette flattens the membrane, reducing tension, and making the response appear to be stretch inactivated. The pronounced latency to activation in patches from mdx mice is caused by the mechanical relaxation time required to reorganize the cortex from inward to outward curvature. The increased latency is equivalent to a three-fold increase in cortical viscosity. Disruption of the cytoskeleton by chemical or mechanical means eliminates the differences in kinetics and curvature between patches from wild-type and mdx mice. The stretch-induced increase in specific capacitance of the patch, approximately 80 fF microm(-2), far exceeds the specific capacitance of bilayers, suggesting the presence of stress-sensitive access to large pools of membrane, possibly caveoli, T-tubules or portions of the gigaseal. In mdx mouse cells the intrinsic gating property of fast voltage-sensitive inactivation is lost. It is robust in wild-type mouse cells (observed in 50% of outside-out patches), but never observed in mdx cells. This link between dystrophin and inactivation may lead to increased background cation currents and Ca2+ influx. Spontaneous Ca2+ transients in mdx mouse cells are sensitive to depolarization and are inhibited by the specific MSC inhibitor GsMTx4, in both the D and L forms.
Collapse
Affiliation(s)
- Thomas M Suchyna
- Department of Physiology and Biophysics, Center for Single Molecule Biophysics, State University New York (SUNY) at Buffalo, Buffalo, NY 14214, USA.
| | | |
Collapse
|
671
|
The dystrotelin, dystrophin and dystrobrevin superfamily: new paralogues and old isoforms. BMC Genomics 2007; 8:19. [PMID: 17233888 PMCID: PMC1790709 DOI: 10.1186/1471-2164-8-19] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2006] [Accepted: 01/17/2007] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Dystrophins and dystrobrevins are distantly related proteins with important but poorly understood roles in the function of metazoan muscular and neuronal tissues. Defects in them and their associated proteins cause a range of neuromuscular disorders. Members of this superfamily have been discovered in a relatively serendipitous way; we set out to compile a comprehensive description of dystrophin- and dystrobrevin-related sequences from available metazoan genome sequences, validated in representative organisms by RT-PCR, or acquired de novo from key species. RESULTS Features of the superfamily revealed by our survey include: a) Dystrotelin, an entirely novel branch of the superfamily, present in most vertebrates examined. Dystrotelin is expressed in the central nervous system, and is a possible orthologue of Drosophila DAH. We describe the preliminary characterisation of its function, evolution and expression. b) A novel vertebrate member of the dystrobrevin family, gamma-dystrobrevin, an ancient branch now extant only in fish, but probably present in our own ancestors. Like dystrophin, zebrafish gamma-dystrobrevin mRNA is localised to myosepta. c) The extent of conservation of alternative splicing and alternative promoter use in the dystrophin and dystrobrevin genes; alternative splicing of dystrophin exons 73 and 78 and alpha-dystrobrevin exon 13 are conserved across vertebrates, as are the use of the Dp116, Dp71 and G-utrophin promoters; the Dp260 and Dp140 promoters are tetrapod innovations. d) The evolution of the unique N-terminus of DRP2 and its relationship to Dp116 and G-utrophin. e) A C-terminally truncated common ancestor of dystrophin and utrophin in cyclostomes. f) A severely restricted repertoire of dystrophin complex components in ascidians. CONCLUSION We have refined our understanding of the evolutionary history and isoform diversity of the five previously reported vertebrate superfamily members and describe two novel members, dystrotelin and gamma-dystrobrevin. Dystrotelins, dystrophins and dystrobrevins are roughly equally related to each other. Vertebrates therefore have a repertoire of seven superfamily members (three dystrophins, three dystrobevins, and one dystrotelin), with one lost in tetrapods. Most invertebrates studied have one member from each branch. Although the basic shared function which is implied by the common architecture of these distantly related proteins remains unclear, it clearly permeates metazoan biology.
Collapse
|
672
|
Peng J, Redman C, Wu X, Song X, Walker RH, Westhoff CM, Lee S. Insights into extensive deletions around the XK locus associated with McLeod phenotype and characterization of two novel cases. Gene 2007; 392:142-50. [PMID: 17300882 PMCID: PMC1931494 DOI: 10.1016/j.gene.2006.11.023] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2006] [Revised: 11/21/2006] [Accepted: 11/27/2006] [Indexed: 11/26/2022]
Abstract
The McLeod phenotype is derived from various forms of XK gene defects that result in the absence of XK protein, and is defined hematologically by the absence of Kx antigen, weakening of Kell system antigens, and red cell acanthocytosis. Individuals with the McLeod phenotype usually develop late-onset neuromuscular abnormalities known as the McLeod syndrome (MLS). MLS is an X-linked multi-system disorder caused by absence of XK alone, or when the disorder is caused by large deletions, it may be accompanied with Duchenne muscular dystrophy (DMD), chronic granulomatous disease (CYBB), retinitis pigmentosa (RPGR), and ornithine transcarbamylase deficiency (OTC). XK defects derived from a large deletion at the XK locus (Xp21.1) have not been characterized at the molecular level. In this study, the deletion breakpoints of two novel cases of McLeod phenotype with extensive deletions are reported. Case 1 has greater than 1.12 million base-pairs (mb) deletion around the XK locus with 7 genes affected. Case 2 has greater than 5.65 mb deletion from TCTE1L to DMD encompassing 20 genes. Phylogenetic analyses demonstrated that DMD, XK and CYBB have close paralogs, some of which may partially substitute for the functions of their counterparts. The loci around XK are highly conserved from fish to human; however, the disorders are probably specific to mammals, and may coincide with the translocation of the loci to the X chromosome after the speciation in birds. The non-synonymous to synonymous nucleotide substitution rate ratio (omega=dN/dS) in these genes was examined. CYBB and RPGR show evidence of positive selection, whereas DMD, XK and OTC are subject to selective constraint.
Collapse
Affiliation(s)
| | | | - Xu Wu
- New York Blood Center, New York, NY 10021, USA
| | | | | | | | - Soohee Lee
- New York Blood Center, New York, NY 10021, USA
| |
Collapse
|
673
|
Esapa CT, Waite A, Locke M, Benson MA, Kraus M, McIlhinney RAJ, Sillitoe RV, Beesley PW, Blake DJ. SGCE missense mutations that cause myoclonus-dystonia syndrome impair ε-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA. Hum Mol Genet 2007; 16:327-42. [PMID: 17200151 DOI: 10.1093/hmg/ddl472] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Myoclonus-dystonia syndrome (MDS) is a genetically heterogeneous disorder characterized by myoclonic jerks often seen in combination with dystonia and psychiatric co-morbidities and epilepsy. Mutations in the gene encoding epsilon-sarcoglycan (SGCE) have been found in some patients with MDS. SGCE is a maternally imprinted gene with the disease being inherited in an autosomal dominant pattern with reduced penetrance upon maternal transmission. In the central nervous system, epsilon-sarcoglycan is widely expressed in neurons of the cerebral cortex, basal ganglia, hippocampus, cerebellum and the olfactory bulb. epsilon-Sarcoglycan is located at the plasma membrane in neurons, muscle and transfected cells. To determine the effect of MDS-associated mutations on the function of epsilon-sarcoglycan we examined the biosynthesis and trafficking of wild-type and mutant proteins in cultured cells. In contrast to the wild-type protein, disease-associated epsilon-sarcoglycan missense mutations (H36P, H36R and L172R) produce proteins that are undetectable at the cell surface and are retained intracellularly. These mutant proteins become polyubiquitinated and are rapidly degraded by the proteasome. Furthermore, torsinA, that is mutated in DYT1 dystonia, a rare type of primary dystonia, binds to and promotes the degradation of epsilon-sarcoglycan mutants when both proteins are co-expressed. These data demonstrate that some MDS-associated mutations in SGCE impair trafficking of the mutant protein to the plasma membrane and suggest a role for torsinA and the ubiquitin proteasome system in the recognition and processing of misfolded epsilon-sarcoglycan.
Collapse
Affiliation(s)
- Christopher T Esapa
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
674
|
Veroni C, Grasso M, Macchia G, Ramoni C, Ceccarini M, Petrucci TC, Macioce P. β-dystrobrevin, a kinesin-binding receptor, interacts with the extracellular matrix components pancortins. J Neurosci Res 2007; 85:2631-9. [PMID: 17265465 DOI: 10.1002/jnr.21186] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The dystrobrevins (alpha and beta) are components of the dystrophin-associated protein complex (DPC), which links the cytoskeleton to the extracellular matrix and serves as a scaffold for signaling proteins. The precise functions of the beta-dystrobrevin isoform, which is expressed in nonmuscle tissues, have not yet been determined. To gain further insights into the role of beta-dystrobrevin in brain, we performed a yeast two-hybrid screen and identified pancortin-2 as a novel beta-dystrobrevin-binding partner. Pancortins-1-4 are neuron-specific olfactomedin-related glycoproteins, highly expressed during brain development and widely distributed in the mature cerebral cortex of the mouse. Pancortins are important constituents of the extracellular matrix and are thought to play an essential role in neuronal differentiation. We characterized the interaction between pancortin-2 and beta-dystrobrevin by in vitro and in vivo association assays and mapped the binding site of pancortin-2 on beta-dystrobrevin to amino acids 202-236 of the beta-dystrobrevin molecule. We also found that the domain of interaction for beta-dystrobrevin is contained in the B part of pancortin-2, a central region that is common to all four pancortins. Our results indicate that beta-dystrobrevin could interact with all members of the pancortin family, implying that beta-dystrobrevin may be involved in brain development. We suggest that dystrobrevin, a motor protein receptor that binds kinesin heavy chain, might play a role in intracellular transport of pancortin to specific sites in the cell.
Collapse
Affiliation(s)
- Caterina Veroni
- Department of Cell Biology and Neuroscience, Istituto Superiore di Sanità, Roma, Italy
| | | | | | | | | | | | | |
Collapse
|
675
|
Anyomi FM, Bior AD, Essenberg RC, Sauer JR. Gene expression in male tick salivary glands is affected by feeding in the presence of females. ARCHIVES OF INSECT BIOCHEMISTRY AND PHYSIOLOGY 2006; 63:159-68. [PMID: 17103403 DOI: 10.1002/arch.20151] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
In this study, we have compared gene expression in the salivary glands of male Dermacentor andersoni ticks fed in the presence or absence of females to that in unfed males. We have established that the patterns of expression are different using arbitrarily primed polymerase chain reaction following reverse transcription of RNA (RAP-PCR) and differential display. Our results indicate a significant difference in salivary gland gene expression between fed and unfed males and also between males fed in the presence of females versus males fed in the absence of females. This difference in expression was partially confirmed by hybridization of probes made from mRNA from the three groups of ticks against the cloned gene fragments. Gene fragments for septin, utrophin, eukaryotic chain release factor 3, and elongation factor 2 were identified in this study, though the majority of fragments were not similar to anything in the databases.
Collapse
Affiliation(s)
- Felix M Anyomi
- Department of Biochemistry and Molecular Biology, Oklahoma State University, Stillwater, OK 74078-3035, USA
| | | | | | | |
Collapse
|
676
|
Mariol MC, Martin E, Chambonnier L, Ségalat L. Dystrophin-dependent muscle degeneration requires a fully functional contractile machinery to occur in C. elegans. Neuromuscul Disord 2006; 17:56-60. [PMID: 17134897 DOI: 10.1016/j.nmd.2006.09.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2006] [Revised: 09/13/2006] [Accepted: 09/18/2006] [Indexed: 11/19/2022]
Abstract
In mammals, the lack of dystrophin leads to a degeneration of skeletal muscles. It has been known for many years that this pathology can be blocked by denervation or immobilization of muscles. It is not yet clear, however, whether this suppressing effect is due to the absence of fiber contraction per se, or to other mechanisms which may be induced by such treatments. We took advantage of the genetic tools available in the animal model Caenorhabditis elegans to address this question. Using RNA interference and existing mutants, we genetically impaired the excitation-contraction cascade at specific points in a dystrophin-deficient C. elegans strain which normally undergoes extensive muscle degeneration. Our data show that reducing sarcomere contraction by slightly impairing the contraction machinery is sufficient to dramatically suppress muscle degeneration. Thus, it is the physical tension exerted on the muscle fibers which is the key deleterious event in the absence of dystrophin.
Collapse
|
677
|
Guttinger M, Tafi E, Battaglia M, Coletta M, Cossu G. Allogeneic mesoangioblasts give rise to alpha-sarcoglycan expressing fibers when transplanted into dystrophic mice. Exp Cell Res 2006; 312:3872-9. [DOI: 10.1016/j.yexcr.2006.08.012] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2006] [Revised: 08/09/2006] [Accepted: 08/16/2006] [Indexed: 10/24/2022]
|
678
|
Rice KM, Preston DL, Neff D, Norton M, Blough ER. Age-Related Dystrophin-Glycoprotein Complex Structure and Function in the Rat Extensor Digitorum Longus and Soleus Muscle. J Gerontol A Biol Sci Med Sci 2006; 61:1119-29. [PMID: 17167152 DOI: 10.1093/gerona/61.11.1119] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
This study tested the hypothesis that age-related changes in the dystrophin-glycoprotein complex (DGC) may precede age-associated alterations in muscle morphology and function. Compared to those in adult (6 month) rats, extensor digitorum longus (EDL) and soleus muscle mass was decreased in old (30 month) and very old (36 month) Fischer 344/NNiaHSD x Brown Norway/BiNia rats. The amount of dystrophin, beta-dystroglycan, and alpha-sarcoglycan increased with aging in the EDL and decreased with aging in the soleus. alpha-Dystroglycan levels were increased with aging in both muscles and displayed evidence of altered glycosylation. Immunostaining for the presence of antibody infiltration and dystrophin following increased muscle stretch suggested that the aging in the soleus was characterized by diminished membrane integrity. Together, these data suggest that aging is associated with alterations in EDL and soleus DGC protein content and localization. These results may implicate the DGC as playing a role in age-associated skeletal muscle remodeling.
Collapse
Affiliation(s)
- Kevin M Rice
- Laboratory of Molecular Physiology, Suite 311, Science Building, Department of Biological Sciences, 1 John Marshall Drive, Marshall University, Huntington, WV 25755-1090, USA
| | | | | | | | | |
Collapse
|
679
|
Rafii MS, Hagiwara H, Mercado ML, Seo NS, Xu T, Dugan T, Owens RT, Hook M, McQuillan DJ, Young MF, Fallon JR. Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. J Cell Physiol 2006; 209:439-47. [PMID: 16883602 PMCID: PMC2929672 DOI: 10.1002/jcp.20740] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The dystrophin-associated protein complex (DAPC), which links the cytoskeleton to the extracellular matrix, is essential for muscle cell survival, and is defective in a wide range of muscular dystrophies. The DAPC contains two transmembrane subcomplexes-the dystroglycans and the sarcoglycans. Although several extracellular binding partners have been identified for the dystroglycans, none have been described for the sarcoglycan subcomplex. Here we show that the small leucine-rich repeat (LRR) proteoglycan biglycan binds to alpha- and gamma-sarcoglycan as judged by ligand blot overlay and co-immunoprecipitation assays. Our studies with biglycan-decorin chimeras show that alpha- and gamma-sarcoglycan bind to distinct sites on the polypeptide core of biglycan. Both biglycan proteoglycan as well as biglycan polypeptide lacking glycosaminoglycan (GAG) side chains are components of the dystrophin glycoprotein complex isolated from adult skeletal muscle membranes. Finally, our immunohistochemical and biochemical studies with biglycan null mice show that the expression of alpha- and gamma-sarcoglycan is selectively reduced in muscle from young (P14-P21) animals, while levels in adult muscle (> or = P35) are unchanged. We conclude that biglycan is a ligand for two members of the sarcoglycan complex and regulates their expression at discrete developmental ages.
Collapse
Affiliation(s)
- Michael S. Rafii
- Department of Neuroscience, Brown University, Providence RI, 02912
| | - Hiroki Hagiwara
- Department of Neuroscience, Brown University, Providence RI, 02912
| | | | | | - Tianshun Xu
- Craniofacial and Skeletal Diseases Branch, National Institutes of Dental Research, National Institutes of Health, Bethesda MD, 20892
| | - Tracey Dugan
- Texas A&M University System Health Science Center Institute of Biosciences and Technology
| | | | - Magnus Hook
- Texas A&M University System Health Science Center Institute of Biosciences and Technology
| | | | - Marian F. Young
- Craniofacial and Skeletal Diseases Branch, National Institutes of Dental Research, National Institutes of Health, Bethesda MD, 20892
| | - Justin R. Fallon
- Department of Neuroscience, Brown University, Providence RI, 02912
| |
Collapse
|
680
|
Sonnemann KJ, Fitzsimons DP, Patel JR, Liu Y, Schneider MF, Moss RL, Ervasti JM. Cytoplasmic gamma-actin is not required for skeletal muscle development but its absence leads to a progressive myopathy. Dev Cell 2006; 11:387-97. [PMID: 16950128 DOI: 10.1016/j.devcel.2006.07.001] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2006] [Revised: 06/21/2006] [Accepted: 07/06/2006] [Indexed: 10/24/2022]
Abstract
Nonmuscle gamma(cyto)-actin is expressed at very low levels in skeletal muscle but uniquely localizes to costameres, the cytoskeletal networks that couple peripheral myofibrils to the sarcolemma. We generated and analyzed skeletal muscle-specific gamma(cyto)-actin knockout (Actg1-msKO) mice. Although muscle development proceeded normally, Actg1-msKO mice presented with overt muscle weakness accompanied by a progressive pattern of muscle fiber necrosis/regeneration. Functional deficits in whole-body tension and isometric twitch force were observed, consistent with defects in the connectivity between muscle fibers and/or myofibrils or at the myotendinous junctions. Surprisingly, gamma(cyto)-actin-deficient muscle did not demonstrate the fibrosis, inflammation, and membrane damage typical of several muscular dystrophies but rather presented with a novel progressive myopathy. Together, our data demonstrate an important role for minimally abundant but strategically localized gamma(cyto)-actin in adult skeletal muscle and describe a new mouse model to study the in vivo relevance of subcellular actin isoform sorting.
Collapse
Affiliation(s)
- Kevin J Sonnemann
- Program in Cellular and Molecular Biology, University of Wisconsin-Madison, 53706, USA
| | | | | | | | | | | | | |
Collapse
|
681
|
Brumitt JW, Essman SC, Kornegay JN, Graham JP, Weber WJ, Berry CR. RADIOGRAPHIC FEATURES OF GOLDEN RETRIEVER MUSCULAR DYSTROPHY. Vet Radiol Ultrasound 2006; 47:574-80. [PMID: 17153067 DOI: 10.1111/j.1740-8261.2006.00188.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Golden Retriever muscular dystrophy is an inherited, degenerative myopathy due to the absence of dystrophin and is used as a model of Duchenne muscular dystrophy of young boys. This report describes the radiographic abnormalities of Golden Retriever muscular dystrophy in 26 dogs. The thoracic abnormalities included diaphragmatic asymmetry (18/26), diaphragmatic undulation (18/26), and gastro-esophageal hiatal hernia (6/26). Pelvic abnormalities included narrowing of the body of the ilia (14/19), ventral deviation and curvature of the tuber ischii (14/19), elongation of the obturator foramen with a decrease in opacity of the surrounding bone (12/19), and lateral flaring of the wings of the ilia (12/19). Abdominal abnormalities consisted of hepatomegaly (14/22) and poor serosal detail (12/22). The unique thoracic abnormalities were a consistent finding in affected Golden Retriever muscular dystrophy dogs. The diagnosis of muscular dystrophy should be included in the differential list if the combination of diaphragm undulation and asymmetry, and gastro-esophageal hiatal hernia are identified. These diaphragmatic abnormalities are related to hypertrophy and hyperplasia of the diaphragm. Additionally, the skeletal changes of pelvic tilt, elongation of the pelvis, widening of the obturator foramina and thinning of the ischiatic tables appear to be specific to Golden Retriever muscular dystrophy in dogs. These pelvic abnormalities are most likely secondary to bone remodeling associated with the progressive skeletal myopathy and subsequent contracture/fibrosis.
Collapse
Affiliation(s)
- Jason W Brumitt
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, 379 East Campus Drive, Columbia, MO 65211, USA
| | | | | | | | | | | |
Collapse
|
682
|
Talbot K, Cho DS, Ong WY, Benson MA, Han LY, Kazi HA, Kamins J, Hahn CG, Blake DJ, Arnold SE. Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. Hum Mol Genet 2006; 15:3041-54. [PMID: 16980328 DOI: 10.1093/hmg/ddl246] [Citation(s) in RCA: 130] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Variations in the gene encoding the novel protein dysbindin-1 (DTNBP1) are among the most commonly reported genetic variations associated with schizophrenia. Recent studies show that those variations are also associated with cognitive functioning in carriers with and without psychiatric diagnoses, suggesting a general role for dysbindin-1 in cognition. Such a role could stem from the protein's known ability to affect neuronal glutamate release. How dysbindin-1 might affect glutamate release nevertheless remains unknown without the discovery of the protein's neuronal binding partners and its subcellular locus of action. We demonstrate here that snapin is a binding partner of dysbindin-1 in vitro and in the brain. Tissue fractionation of whole mouse brains and human hippocampal formations revealed that both dysbindin-1 and snapin are concentrated in tissue enriched in synaptic vesicle membranes and less commonly in postsynaptic densities. It is not detected in presynaptic tissue fractions lacking synaptic vesicles. Consistent with that finding, immunoelectron microscopy showed that dysbindin-1 is located in (i) synaptic vesicles of axospinous terminals in the dentate gyrus inner molecular layer and CA1 stratum radiatum and in (ii) postsynaptic densities and microtubules of dentate hilus neurons and CA1 pyramidal cells. The labeled synapses are often asymmetric with thick postsynaptic densities suggestive of glutamatergic synapses, which are likely to be derived from dentate mossy cells and CA3 pyramidal cells. The function of dysbindin-1 in presynaptic, postsynaptic and microtubule locations may all be related to known functions of snapin.
Collapse
Affiliation(s)
- Konrad Talbot
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
683
|
Boittin FX, Petermann O, Hirn C, Mittaud P, Dorchies OM, Roulet E, Ruegg UT. Ca2+-independent phospholipase A2 enhances store-operated Ca2+ entry in dystrophic skeletal muscle fibers. J Cell Sci 2006; 119:3733-42. [PMID: 16926189 DOI: 10.1242/jcs.03184] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Duchenne muscular dystrophy is caused by deficiency of dystrophin and leads to progressive weakness. It has been proposed that the muscle degeneration occurring in this disease is caused by increased Ca2+ influx due to enhanced activity of cationic channels that are activated either by stretch of the plasma membrane (stretch-activated channels) or by Ca2+-store depletion (store-operated channels). Using both cytosolic Ca2+ measurements with Fura-2 and the manganese quench method, we show here that store-operated Ca2+ entry is greatly enhanced in dystrophic skeletal flexor digitorum brevis fibers isolated from mdx5cv mice, a mouse model of Duchenne muscular dystrophy. Moreover, we show for the first time that store-operated Ca2+ entry in these fibers is under the control of the Ca2+-independent phospholipase A2 and that the exaggerated Ca2+ influx can be completely attenuated by inhibitors of this enzyme. Enhanced store-operated Ca2+ entry in dystrophic fibers is likely to be due to a near twofold overexpression of Ca2+-independent phospholipase A2. The Ca2+-independent phospholipase A2 pathway therefore appears as an attractive target to reduce excessive Ca2+ influx and subsequent degeneration occurring in dystrophic fibers.
Collapse
Affiliation(s)
- François-Xavier Boittin
- Laboratory of Pharmacology, Geneva-Lausanne School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneva 4, Switzerland
| | | | | | | | | | | | | |
Collapse
|
684
|
Souchelnytskyi S, Lomnytska M, Dubrovska A, Hellman U, Volodko N. Proteomics Success Story. Towards Early Detection of Breast and Ovarian Cancer: Plasma Proteomics as a Tool to Find Novel Markers. Proteomics 2006; 6 Suppl 2:65-8. [PMID: 17031801 DOI: 10.1002/pmic.200600462] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
685
|
Mulè F, Amato A, Vannucchi MG, Faussone-Pellegrini MS, Serio R. Altered tachykinergic influence on gastric mechanical activity in mdx mice. Neurogastroenterol Motil 2006; 18:844-52. [PMID: 16918764 DOI: 10.1111/j.1365-2982.2006.00820.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
This study investigated whether alterations in gastric activity in dystrophic mdx mouse can be attributed to dysfunctions of tachykinins. Endoluminal pressure was recorded and the expression of neuronal nitric oxide synthase (nNOS), NK1 and NK2 neurokinin receptors was investigated by immunohistochemistry. SR48968, NK2 receptor antagonist, but not SR140333, NK1 receptor antagonist, decreased the tone only in mdx gastric preparations. In the presence of N(omega)-nitro-l-arginine methyl ester (l-NAME), inhibitor of NOS, SR48968 reduced the tone also in normal stomach. [Sar(9), Met(O(2))(11)]-SP, agonist of NK1 receptors, caused tetrodotoxin-sensitive relaxations, antagonized by SR140333 or l-NAME, with no difference in the potency or efficacy between normal and mdx preparations. [beta-Ala(8)]-NKA(4-10), an NK2 receptor agonist, induced SR48968-sensitive contractions in both types of preparations, although the maximal response of mdx tissues was significantly lower than normal preparations. Immunohistochemistry demonstrated a consistent reduction of nNOS and NK2 receptor expression in mdx stomach smooth muscle cells and no change in nNOS and NK1 receptor expression in neurones. In conclusion, in mdx stomach the activation of NK2 receptors plays a role in the development of the tone, associated with a reduced NO production by muscular nNOS. The hypo-responsiveness to NK2 receptors could depend on the reduced expression of these receptors.
Collapse
Affiliation(s)
- F Mulè
- Dipartimento di Biologia Cellulare e dello Sviluppo, Laboratorio di Fisiologia generale, Università di Palermo, Palermo, Italy.
| | | | | | | | | |
Collapse
|
686
|
Constantin B, Sebille S, Cognard C. New insights in the regulation of calcium transfers by muscle dystrophin-based cytoskeleton: implications in DMD. J Muscle Res Cell Motil 2006; 27:375-86. [PMID: 16897576 DOI: 10.1007/s10974-006-9085-2] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2006] [Accepted: 06/28/2006] [Indexed: 01/18/2023]
Abstract
Calcium mishandling in Duchenne muscular dystrophy (DMD) suggested that dystrophin, a membrane-associated cytoskeleton protein, may regulate calcium-signalling cascades such as calcium entries. Calcium overload in human DMD myotubes is dependent on their contractile activity suggesting the involvement of channels being activated during contraction and/or calcium release. Forced expression of mini-dystrophin in dystrophin-deficient myotubes, reactivates appropriate sarcolemmal expression of dystrophin-associated proteins and restores normal calcium handling in the cytosol. Furthermore, the recombinant mini-dystrophin reduced the store-operated calcium influx across the sarcolemma, and the mitochondrial calcium uptake during this influx. A slow component of calcium release dependent on IP3R, as well as the production of IP3, were also reduced to normal levels by expression of mini-dystrophin. Our studies provide a new model for the convergent regulation of transmembrane calcium influx and IP3-dependent calcium release by the dystrophin-based cytoskeleton (DBC). We also suggest molecular association of such channels with DBC which may provide the scaffold for assembling a multiprotein-signalling complex that modulates the channel activity. This suggests that the loss of this molecular association could participate in the alteration of calcium homeostasis observed in DMD muscle cells.
Collapse
Affiliation(s)
- Bruno Constantin
- Institut de Physiologie et Biologie Cellulaires, CNRS, UMR-6187, University of Poitiers, 86022, Poitiers, France.
| | | | | |
Collapse
|
687
|
Cerna J, Cerecedo D, Ortega A, García-Sierra F, Centeno F, Garrido E, Mornet D, Cisneros B. Dystrophin Dp71f associates with the beta1-integrin adhesion complex to modulate PC12 cell adhesion. J Mol Biol 2006; 362:954-65. [PMID: 16935300 PMCID: PMC1952692 DOI: 10.1016/j.jmb.2006.07.075] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2006] [Revised: 07/25/2006] [Accepted: 07/26/2006] [Indexed: 02/04/2023]
Abstract
Dystrophin Dp71 is the main product of the Duchenne muscular dystrophy gene in the brain; however, its function is unknown. To study the role of Dp71 in neuronal cells, we previously generated by antisense treatment PC12 neuronal cell clones with decreased Dp71 expression (antisense-Dp71 cells). PC12 cells express two different splicing isoforms of Dp71, a cytoplasmic variant called Dp71f and a nuclear isoform called Dp71d. We previously reported that antisense-Dp71 cells display deficient adhesion to substrate and reduced immunostaining of beta1-integrin in the cell area contacting the substrate. In this study, we isolated additional antisense-Dp71 clones to analyze in detail the potential involvement of Dp71f isoform with the beta1-integrin adhesion system of PC12 cells. Immunofluorescence analyses as well as immunoprecipitation assays demonstrated that the PC12 cell beta1-integrin adhesion complex is composed of beta1-integrin, talin, paxillin, alpha-actinin, FAK and actin. In addition, our results showed that Dp71f associates with most of the beta1-integrin complex components (beta1-integrin, FAK, alpha-actinin, talin and actin). In the antisense-Dp71 cells, the deficiency of Dp71 provokes a significant reduction of the beta1-integrin adhesion complex and, consequently, the deficient adhesion of these cells to laminin. In vitro binding experiments confirmed the interaction of Dp71f with FAK and beta1-integrin. Our data indicate that Dp71f is a structural component of the beta1-integrin adhesion complex of PC12 cells that modulates PC12 cell adhesion by conferring proper complex assembly and/or maintenance.
Collapse
Affiliation(s)
- Joel Cerna
- Departmento de Génética y Biologia Molecular
Centro de Investigacion y de Estufios Avanzados del I.P.N.Av. Instituto Politécnico Nacional 2508, Col. San PedroZacatenco, México, D. F. 07360,MX
| | - Doris Cerecedo
- Laboratorio de Hematologia
Escuela Superior de medecina y Homeopatia I.P.N.Wilfrido Massieu Helguera 239 Frac. La Escalera Ticomán. México, D. F. 07320,MX
| | - Arturo Ortega
- Departmento de Génética y Biologia Molecular
Centro de Investigacion y de Estufios Avanzados del I.P.N.Av. Instituto Politécnico Nacional 2508, Col. San PedroZacatenco, México, D. F. 07360,MX
| | - Francisco García-Sierra
- Deparmento de Biologia Cellular
Centro de Investigacion y de Estudios Avanzados del I.P.N.Av. Instituto Politécnico Nacional 2508 Col. San Pedro Zacatenco, México, D. F. 07360,MX
| | - Federico Centeno
- Departmento de Génética y Biologia Molecular
Centro de Investigacion y de Estufios Avanzados del I.P.N.Av. Instituto Politécnico Nacional 2508, Col. San PedroZacatenco, México, D. F. 07360,MX
| | - Efrain Garrido
- Departmento de Génética y Biologia Molecular
Centro de Investigacion y de Estufios Avanzados del I.P.N.Av. Instituto Politécnico Nacional 2508, Col. San PedroZacatenco, México, D. F. 07360,MX
| | - Dominique Mornet
- Muscles et pathologies chroniques
Université Montpellier I EA701Institut de Biologie, Boulevard Henry IV, 34062 Montpellier,FR
| | - Bulmaro Cisneros
- Departmento de Génética y Biologia Molecular
Centro de Investigacion y de Estufios Avanzados del I.P.N.Av. Instituto Politécnico Nacional 2508, Col. San PedroZacatenco, México, D. F. 07360,MX
- * Correspondence should be adressed to: Cisneros Bulmaro
| |
Collapse
|
688
|
Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead. Chin Med J (Engl) 2006. [DOI: 10.1097/00029330-200608020-00011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
689
|
Bhosle RC, Michele DE, Campbell KP, Li Z, Robson RM. Interactions of intermediate filament protein synemin with dystrophin and utrophin. Biochem Biophys Res Commun 2006; 346:768-77. [PMID: 16777071 DOI: 10.1016/j.bbrc.2006.05.192] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2006] [Accepted: 05/25/2006] [Indexed: 01/06/2023]
Abstract
Synemin is a unique, very large intermediate filament (IF) protein present in all types of muscle cells, which forms heteropolymeric intermediate filaments (IFs) with the major IF proteins desmin and/or vimentin. We show herein that tissue-purified avian synemin directly interacts with both dystrophin and utrophin, and that specific expressed regions of both of the mammalian (human) synemin isoforms (alpha-synemin and beta-synemin) directly interact with specific expressed domains/regions of the dystrophin and utrophin molecules. Mammalian synemin is also shown to colocalize with dystrophin within muscle cell cultures. These results indicate that synemin is an important IF protein in muscle cells that helps fortify the linkage between the peripheral layer of cellular myofibrils and the costameric regions located along the sarcolemma and the sarcolemma region located within the neuromuscular and myotendinous junctions (NMJs and MTJs).
Collapse
Affiliation(s)
- Rahul C Bhosle
- Muscle Biology Group, Department of Biochemistry, Iowa State University, Ames, IA 50011-3260, USA
| | | | | | | | | |
Collapse
|
690
|
Calderilla-Barbosa L, Ortega A, Cisneros B. Phosphorylation of dystrophin Dp71d by Ca2+/calmodulin-dependent protein kinase II modulates the Dp71d nuclear localization in PC12 cells. J Neurochem 2006; 98:713-22. [PMID: 16893417 DOI: 10.1111/j.1471-4159.2006.03904.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
We have shown that the splicing isoform of Dp71 (Dp71d) localizes to the nucleus of PC12 cells, an established cell line derived from a rat pheochromocytoma; however, the mechanisms governing its nuclear localization are unknown. As protein phosphorylation modulates the nuclear import of proteins, and as Dp71d presents several potential sites for phosphorylation, we analyzed whether Dp71d is phosphorylated in PC12 cells and the role of phosphorylation on its nuclear localization. We demonstrated that Dp71d is phosphorylated under basal conditions at serine and threonine residues by endogenous protein kinases. Dp71d phosphorylation was activated by 2-O-tetradecanoyl phorbol 13-acetate (TPA), but this effect was blocked by EGTA. Supporting the role of intracellular calcium on Dp71d phosphorylation, we observed that the stimulation of calcium influx by cell depolarization increased Dp71d phosphorylation, and that the calcium-calmodulin inhibitor N-(6-aminohexyl)-1-naphthalenesulfonamide (W-7) blocked such induction. The blocking action of bisindolylmaleimide I (Bis I), a specific inhibitor for Ca2+/diacylglicerol-dependent protein kinase (PKC), on Dp71d phosphorylation suggested the participation of PKC in this event. In addition, transfection experiments with Ca2+/calmodulin-dependent protein kinase II (CaMKII) expression vectors as well as the use of KN-62, a CaMKII-specific inhibitor, demonstrated that CaMKII is also involved in Dp71d phosphorylation. Stimulation of Dp71d phosphorylation by cell depolarization and/or the overexpression of CaMKII favored the Dp71d nuclear accumulation. Overall, our results indicate that CAMKII-mediated Dp71d phosphorylation modulates its nuclear localization.
Collapse
Affiliation(s)
- Luis Calderilla-Barbosa
- Genetics and Molecular Biology Department, Centro de Investigación y de Estudios Avanzados del IPN, San Pedro Zacatenco, Mexico
| | | | | |
Collapse
|
691
|
Allard B. Sarcolemmal ion channels in dystrophin-deficient skeletal muscle fibres. J Muscle Res Cell Motil 2006; 27:367-73. [PMID: 16874448 DOI: 10.1007/s10974-006-9083-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2006] [Accepted: 06/26/2006] [Indexed: 11/29/2022]
Abstract
Duchenne muscular dystrophy (DMD) is a genetic disease caused by mutations in the dystrophin gene and characterized by progressive skeletal muscle degeneration. A current hypothesis suggests that degeneration of dystrophin-deficient skeletal muscle results from a chronic intracellular Ca2+ overload. Ca2+ handling in skeletal muscle is tightly controlled by the membrane potential which is set by sarcolemmal ion channels activity. Also, with regard to the subsarcolemmal localization of dystrophin, it is reasonable to enquire if the distribution and function of ion channels might be affected by the absence of dystrophin. This paper briefly summarizes the current knowledge of the properties of sarcolemmal ion channels in fully differentiated dystrophin-deficient skeletal muscle fibres.
Collapse
Affiliation(s)
- Bruno Allard
- Physiologie Intégrative, Cellulaire et Moléculaire, UMR CNRS 5123, Université C. Bernard Lyon 1, 43 bd du 11 Novembre 1918, 69622, Villeurbanne cedex, France.
| |
Collapse
|
692
|
Lien CF, Hazai D, Yeung D, Tan J, Füchtbauer EM, Jancsik V, Górecki DC. Expression of alpha-dystrobrevin in blood-tissue barriers: sub-cellular localisation and molecular characterisation in normal and dystrophic mice. Cell Tissue Res 2006; 327:67-82. [PMID: 16868787 DOI: 10.1007/s00441-006-0241-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2006] [Accepted: 05/09/2006] [Indexed: 11/30/2022]
Abstract
The alpha- and beta-dystrobrevins (DBs) belong to a family of dystrophin-related and dystrophin-associated proteins that are members of the dystrophin-associated protein complex (DAPC). This complex provides a link between the cytoskeleton and the extracellular matrix or other cells. However, specific functions of the two dystrobrevins remain largely unknown, with alpha-DB being believed to have a role mainly in skeletal muscle. Here, we describe previously unknown expression patterns and the localisation and molecular characteristics of alpha-DB isoforms in non-muscle mouse tissues. We demonstrate a highly specific sub-cellular distribution of alpha-DB in organs forming blood-tissue barriers. We show alpha-DB expression and localisation in testicular Sertoli cells, stomach and respiratory epithelia and provide electron-microscopic evidence for its immunolocalisation in these cells and in the central nervous system. Moreover, we present the molecular characterisation of alpha-DB transcript in these tissues and provide evidence for a distinct heterogeneity of associations between alpha-DB and dystrophins and utrophin in normal and dystrophic non-muscle tissues. Together, our results indicate that alpha-DB, in addition to its role in skeletal muscle, may also be required for the proper function of specific non-muscle tissues and that disruption of DAPC might lead to tissue-blood barrier abnormalities.
Collapse
Affiliation(s)
- Chun Fu Lien
- Molecular Medicine, Institute of Biomedical and Biomolecular Sciences, School of Pharmacy and Biomedical Sciences, University of Portsmouth, St. Michael's Building, White Swan Road, Portsmouth, UK
| | | | | | | | | | | | | |
Collapse
|
693
|
Abstract
Calpains are Ca2+ -dependent cytosolic cysteine proteases that participate in the pathology of Duchenne muscular dystrophy (DMD). Utrophin is a functional homolog of dystrophin that partially compensates for dystrophin deficiency in myofibers of mdx mice. In this study, we investigated the susceptibility of utrophin to cleavage by calpain in vitro and in muscle cells. We found that utrophin is a direct in vitro substrate of purified calpain I and II. Cleavage of utrophin by calpain I or II generates specific degradation products that are also found in cultured control and DMD myotubes under conditions with elevated intracellular Ca2+ levels. In addition, we showed that activation of cellular calpains by Ca2+ ionophore treatment reduces utrophin protein levels in muscle cells and that calpain inhibition prevents this Ca2+ -induced reduction in utrophin levels. These observations suggest that, beside its known effect on general muscle protein degradation, calpain contributes to DMD pathology by specifically degrading the compensatory protein utrophin.
Collapse
|
694
|
Gavillet B, Rougier JS, Domenighetti AA, Behar R, Boixel C, Ruchat P, Lehr HA, Pedrazzini T, Abriel H. Cardiac sodium channel Nav1.5 is regulated by a multiprotein complex composed of syntrophins and dystrophin. Circ Res 2006; 99:407-14. [PMID: 16857961 DOI: 10.1161/01.res.0000237466.13252.5e] [Citation(s) in RCA: 168] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The cardiac sodium channel Na(v)1.5 plays a key role in cardiac excitability and conduction. The purpose of this study was to elucidate the role of the PDZ domain-binding motif formed by the last three residues (Ser-Ile-Val) of the Na(v)1.5 C-terminus. Pull-down experiments were performed using Na(v)1.5 C-terminus fusion proteins and human or mouse heart protein extracts, combined with mass spectrometry analysis. These experiments revealed that the C-terminus associates with dystrophin, and that this interaction was mediated by alpha- and beta-syntrophin proteins. Truncation of the PDZ domain-binding motif abolished the interaction. We used dystrophin-deficient mdx(5cv) mice to study the role of this protein complex in Na(v)1.5 function. Western blot experiments revealed a 50% decrease in the Na(v)1.5 protein levels in mdx(5cv) hearts, whereas Na(v)1.5 mRNA levels were unchanged. Patch-clamp experiments showed a 29% decrease of sodium current in isolated mdx(5cv) cardiomyocytes. Finally, ECG measurements of the mdx(5cv) mice exhibited a 19% reduction in the P wave amplitude, and an 18% increase of the QRS complex duration, compared with controls. These results indicate that the dystrophin protein complex is required for the proper expression and function of Na(v)1.5. In the absence of dystrophin, decreased sodium current may explain the alterations in cardiac conduction observed in patients with dystrophinopathies.
Collapse
Affiliation(s)
- Bruno Gavillet
- Department of Pharmacology and Toxicology, University of Lausanne, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
695
|
Jane DT, Morvay L, Dasilva L, Cavallo-Medved D, Sloane BF, Dufresne MJ. Cathepsin B localizes to plasma membrane caveolae of differentiating myoblasts and is secreted in an active form at physiological pH. Biol Chem 2006; 387:223-34. [PMID: 16497156 DOI: 10.1515/bc.2006.030] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Our in vitro studies support a functional link between the induction of cathepsin B gene expression and the catabolic restructuring associated with myotube formation during myogenesis in vivo. We have tested two predictions that are basic to this hypothesis: (1) that active cathepsin B is localized to plasma membrane caveolae of fusing myoblasts; and (2) that active cathepsin B is secreted from fusing myoblasts at physiological pH. During differentiation, L6 rat myoblasts demonstrated a fusion-related increase in activity associated with the 25/26-kDa, fully processed, active form of cathepsin B. Immunocytochemical studies demonstrated a redistribution of lysosomal cathepsin B protein toward the membrane of fusing myoblasts, and a colocalization of cathepsin B with caveolin-3, the muscle-specific structural protein of membrane caveolae. Sucrose density fractionation and Western blot analysis demonstrated that an active form of cathepsin B localizes to caveolar fractions along with caveolin-3, annexin-VII, beta-dystroglycan and dystrophin. Finally, 'real-time' activity assays and Western blot analysis demonstrated that active cathepsin B is secreted from fusing myoblasts at physiological pH. Collectively, these studies support an association of active cathepsin B with plasma membrane caveolae and the secretion of active cathepsin B from differentiating myoblasts during myoblast fusion.
Collapse
Affiliation(s)
- Derek T Jane
- Biological Sciences, University of Windsor, Windsor N9B 3P4, ON, Canada
| | | | | | | | | | | |
Collapse
|
696
|
Mercado ML, Amenta AR, Hagiwara H, Rafii MS, Lechner B, Owens RT, McQuillan DJ, Froehner SC, Fallon JR. Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J 2006; 20:1724-6. [PMID: 16807372 PMCID: PMC3056440 DOI: 10.1096/fj.05-5124fje] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The dystrophin-associated protein complex (DAPC) provides a linkage between the cytoskeleton and the extracellular matrix (ECM) and is also a scaffold for a host of signaling molecules. The constituents of the DAPC must be targeted to the sarcolemma in order to properly function. Biglycan is an ECM molecule that associates with the DAPC. Here, we show that biglycan null mice exhibit a mild dystrophic phenotype and display a selective reduction in the localization of alpha-dystrobrevin-1 and -2, alpha- and beta1-syntrophin, and nNOS at the sarcolemma. Purified biglycan induces nNOS redistribution to the plasma membrane in cultured muscle cells. Biglycan protein injected into muscle becomes stably associated with the sarcolemma and ECM for at least 2 wk. This injected biglycan restores the sarcolemmal expression of alpha-dystrobrevin-1 and -2, and beta1- and beta2-syntrophin in biglycan null mice. We conclude that biglycan is important for the maintenance of muscle cell integrity and plays a direct role in regulating the expression and sarcolemmal localization of the intracellular signaling proteins dystrobrevin-1 and -2, alpha- and beta1-syntrophin and nNOS.
Collapse
Affiliation(s)
| | - Alison R. Amenta
- Department of Neuroscience, Brown University, Providence, RI, 02912
| | - Hiroki Hagiwara
- Department of Neuroscience, Brown University, Providence, RI, 02912
| | - Michael S. Rafii
- Department of Neuroscience, Brown University, Providence, RI, 02912
| | - Beatrice Lechner
- Department of Neuroscience, Brown University, Providence, RI, 02912
| | | | | | - Stanley C. Froehner
- Department of Physiology and Biophysics, University of Washington, Seattle, WA 98195
| | - Justin R. Fallon
- Department of Neuroscience, Brown University, Providence, RI, 02912
| |
Collapse
|
697
|
Carre-Pierrat M, Mariol MC, Chambonnier L, Laugraud A, Heskia F, Giacomotto J, Ségalat L. Blocking of striated muscle degeneration by serotonin in C. elegans. J Muscle Res Cell Motil 2006; 27:253-8. [PMID: 16791712 DOI: 10.1007/s10974-006-9070-9] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2005] [Accepted: 04/30/2006] [Indexed: 12/31/2022]
Abstract
Prevention of muscle fiber degeneration is a key issue in the treatment of muscular dystrophies such as Duchenne Muscular Dystrophy (DMD). It is widely postulated that existing pharmaceutical compounds might potentially be beneficial to DMD patients, but tools to identify them are lacking. Here, by using a Caenorhabditis elegans model of dystrophin-dependent muscular dystrophy, we show that the neurohormone serotonin and some of its agonists are potent suppressors of muscle degeneration. Inhibitors of serotonin reuptake transporters, which prolong the action of endogenous serotonin, have a similar effect. Moreover, reduction of serotonin levels leads to degeneration of non-dystrophic muscles. Our results demonstrate that serotonin is critical to C. elegans striated muscles. These findings reveal a new function of serotonin in striated muscles.
Collapse
Affiliation(s)
- Maité Carre-Pierrat
- CGMC, CNRS-UMR 5534, Université Lyon 1, 43 bld du 11 Novembre, 69622 Villeurbanne Cedex, France
| | | | | | | | | | | | | |
Collapse
|
698
|
Ito K, Kimura S, Ozasa S, Matsukura M, Ikezawa M, Yoshioka K, Ueno H, Suzuki M, Araki K, Yamamura KI, Miwa T, Dickson G, Thomas GD, Miike T. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Hum Mol Genet 2006; 15:2266-75. [PMID: 16777842 DOI: 10.1093/hmg/ddl151] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Duchenne muscular dystrophy (DMD) is a fatal X-linked muscle-wasting disease caused by mutations of the gene encoding the cytoskeletal protein dystrophin. Therapeutic options for DMD are limited because the pathogenetic mechanism by which dystrophin deficiency produces the clinical phenotype remains obscure. Recent reports of abnormal alpha-adrenergic vasoregulation in the exercising muscles of DMD patients and in the mdx mouse, an animal model of DMD, prompted us to hypothesize that the dystrophin-deficient smooth muscle contributes to the vascular and dystrophic phenotypes of DMD. To test this, we generated transgenic mdx mice that express dystrophin only in smooth muscle (SMTg/mdx). We found that alpha-adrenergic vasoconstriction was markedly attenuated in the contracting hindlimbs of C57BL/10 wild-type mice, an effect that was mediated by nitric oxide (NO) and was severely impaired in the mdx mice. SMTg/mdx mice showed an intermediate phenotype, with partial restoration of the NO-dependent modulation of alpha-adrenergic vasoconstriction in active muscle. In addition, the elevated serum creatine kinase levels observed in mdx mice were significantly reduced in SMTg/mdx mice. This is the first report of a functional role of dystrophin in vascular smooth muscle.
Collapse
MESH Headings
- Animals
- Base Sequence
- Creatine Kinase/blood
- DNA, Complementary/genetics
- Dystrophin/genetics
- Dystrophin/physiology
- Female
- Gene Expression
- Humans
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Inbred mdx
- Mice, Transgenic
- Muscle Contraction
- Muscle, Smooth, Vascular/blood supply
- Muscle, Smooth, Vascular/physiopathology
- Muscular Dystrophy, Animal/genetics
- Muscular Dystrophy, Animal/pathology
- Muscular Dystrophy, Animal/physiopathology
- Muscular Dystrophy, Duchenne/genetics
- Muscular Dystrophy, Duchenne/physiopathology
- Nitric Oxide Synthase/antagonists & inhibitors
- Receptors, Adrenergic, alpha/physiology
- Vasoconstriction
Collapse
Affiliation(s)
- Kaori Ito
- Department of Child Development, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University Graduate School, Kumamoto 860-0811, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
699
|
Ervasti JM. Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim Biophys Acta Mol Basis Dis 2006; 1772:108-17. [PMID: 16829057 DOI: 10.1016/j.bbadis.2006.05.010] [Citation(s) in RCA: 220] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2006] [Revised: 05/31/2006] [Accepted: 05/31/2006] [Indexed: 11/27/2022]
Abstract
Duchenne muscular dystrophy is the most prevalent and severe form of human muscular dystrophy. Investigations into the molecular basis for Duchenne muscular dystrophy were greatly facilitated by seminal studies in the 1980s that identified the defective gene and its major protein product, dystrophin. Biochemical studies revealed its tight association with a multi-subunit complex, the so-named dystrophin-glycoprotein complex. Since its description, the dystrophin-glycoprotein complex has emerged as an important structural unit of muscle and also as a critical nexus for understanding a diverse array of muscular dystrophies arising from defects in several distinct genes. The dystrophin homologue utrophin can compensate at the cell/tissue level for dystrophin deficiency, but functions through distinct molecular mechanisms of protein-protein interaction.
Collapse
Affiliation(s)
- James M Ervasti
- Department of Physiology, 127 Service Memorial Institute, University of Wisconsin Medical School, 1300 University Avenue, Madison, WI 53706, USA.
| |
Collapse
|
700
|
Mulè F, Zizzo MG, Amato A, Feo S, Serio R. Evidence for a role of inducible nitric oxide synthase in gastric relaxation of mdx mice. Neurogastroenterol Motil 2006; 18:446-54. [PMID: 16700724 DOI: 10.1111/j.1365-2982.2006.00782.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Alterations of gastric mechanical activity have been reported in mdx mouse, animal model for Duchenne muscular dystrophy. This study examined if alterations in the vasoactive intestinal polypeptide (VIP) system are present in mdx stomach. Gastric mechanical activity was recorded in vitro as changes of endoluminal pressure and neurally or pharmacologically evoked relaxations were analysed in mdxvs normal stomach. Reverse-transcription polymerase chain reaction was used to detect inducible nitric oxide synthase (iNOS) expression. Relaxations to sodium nitroprusside in mdx stomach showed no difference in comparison with normal preparations. In normal stomach, VIP produced relaxation, which was reduced by VIP6-28, antagonist of VIP receptors, but was not modified by Nomega-nitro-L-arginine methyl ester (L-NAME), 1-H-oxodiazol-[1,2,4]-[4,3-a]quinoxaline-1-one (ODQ) or by N-(3-(aminomethyl)-benzyl)acetamidine (1400W) and aminoguanidine, inhibitors of iNOS. In contrast, in mdx stomach VIP responses were antagonized not only by VIP6-28, but also by L-NAME, ODQ, 1400W or aminoguanidine. In normal stomach, the slow relaxation evoked by stimulation at high frequency was reduced by VIP6-28, but it was unaffected by 1400W or aminoguanidine. In mdx stomach, it was reduced by VIP6-28 or 1400W, which did not show additive effects. iNOS mRNA was expressed only in mdx stomach. The results suggest that in mdx gastric preparations, iNOS is functionally expressed, being involved in the slow relaxation induced by VIP.
Collapse
Affiliation(s)
- F Mulè
- Dipartimento di Biologia cellulare e dello Sviluppo, Laboratorio di Fisiologia Generale, Università di Palermo, Palermo, Italy.
| | | | | | | | | |
Collapse
|